Presented on .
Newborn screening began in the United States in the 1960s to test for medical conditions that may not be apparent just by looking at a baby. Finding these conditions soon after birth can help prevent certain serious problems, such as brain damage, organ damage, and even death. The traditional method of newborn screening is bloodspot testing, wherein blood is sent to a lab to be screened for a number of conditions. There is also a newer paradigm of point-of-care newborn screening to test for hearing loss and critical congenital heart defects, conditions that are not identifiable through blood tests.
Both traditional bloodspot screening and the newer point-of-care screening tests share the goals of making sure that newborns are tested for certain potentially life-threatening conditions, and ensuring that providers follow up based on test results. The newer tests, however, do pose some unique challenges for public health. Because these tests take place in the health care setting rather than in a lab, it is difficult to standardize both the implementation of the tests and reporting of the test results. Newborn screening is also mandated by each individual state, so tests required in some states may not be in others.
In this session of Public Health Grand Rounds, you will hear how some states have implemented point-of-care newborn screening and what challenges they have faced in standardizing these tests and tracking test results. Speakers will also discuss how public health partners at all levels can work toward ensuring that every baby is screened.
Beyond the Data
- Stuart K. Shapira, MD, PhD
- Associate Director for Science
National Center on Birth Defects and Developmental Disabilities, CDC
- Marci K. Sontag, PhD
- Associate Professor of Epidemiology
University of Colorado Anschutz Medical Campus
- Kim Van Naarden Braun, PhD
- Epidemiologist, Division of Family Health Services
New Jersey Department of Health
- Craig A. Mason, PhD
- Professor of Education and Applied Quantitative Methods
University of Maine
- John Iskander, MD, MPH
- Scientific Director
- Phoebe Thorpe, MD, MPH
- Deputy Scientific Director
- Susan Laird, MSN, RN
- Communications Director
Enjoyed this Presentation?
You May Also Like
More than 4 million newborns in the US are screened yearly for hearing loss and certain disorders. Learn how newborn screening provides an opportunity for reductions in morbidity and mortality while reducing health care costs associated with treatment of lifelong debilitating conditions.
Neonatal Abstinence Syndrome (NAS) occurs when newborn babies experience withdrawal after being exposed to drugs in the womb. It can occur with illicit and prescription drugs, including prescription opioids. Find out what CDC is doing with state and local partners to develop better opioid prescribing policies.
- Page last reviewed: February 28, 2018
- Page last updated: February 28, 2018
- Content source:
- Office of the Associate Director for Science
- Page maintained by: Office of the Associate Director for Communication